Shots: GSK to get rights to develop and commercialize three additional inhaled therapies utilizing Liquidia’s PRINT technology and can acquire rights to pursue additional PRINT based inhalation therapies. Liquidia to […]readmore
Tags : Liquidia
Shots: The study involves assessing of LIQ861 in 109 patients divided in two groups of 65 prostacyclin-naive patients that were stable on ≤2 approved oral PAH therapies and 44 patients […]readmore